Immune Checkpoint Inhibitors and Venous Thromboembolism: The More Things Change…

Alok A. Khorana

doi:10.1055/a-2121-9679

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2023; 123(11): 1057-1059
DOI: 10.1055/a-2121-9679

Invited Editorial Focus

Immune Checkpoint Inhibitors and Venous Thromboembolism: The More Things Change…

Authors

Alok A. Khorana

¹Department of Hematology Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

²Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Abstract

Full Text

References

References
1 Lecumberri R, Ruiz-Artacho P, Tzoran I. et al; RIETE Investigators. Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. Thromb Haemost 2022; 122 (09) 1594-1602
2 Wiredu C, Haynes N, Guerra C, Ky B. Racial and ethnic disparities in cancer-associated thrombosis. Thromb Haemost 2022; 122 (05) 662-665
3 Johnson PC, Gainor JF, Sullivan RJ, Longo DL, Chabner B. Immune checkpoint inhibitors - the need for innovation. N Engl J Med 2023; 388 (16) 1529-1532
4 Xu K, Chan NC. Recurrent thrombosis and bleeding in patients with cancer-associated venous thromboembolism receiving anticoagulation: are these modifiable risk factors for mortality?. Thromb Haemost 2023; 123 (05) 487-489
5 Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378 (02) 158-168
6 McBane Ii RD, Vlazny DT, Houghton D. et al. Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment. Thromb Haemost 2023; 123 (05) 535-544
7 Kim SA, Lee JH, Lee JY. et al. Treatment and bleeding complications of cancer-associated venous thromboembolism: a Korean population-based study. Thromb Haemost 2022; 122 (12) 2011-2018
8 le Sève JD, Guédon AF, Bordenave S. et al. Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor. Thromb Haemost 2023; 123 (11) 1049-1056
9 Wang T-F, Carrier M. Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management. Curr Oncol 2023; 30 (03) 3032-3046
10 Ma Z, Sun X, Zhang Y. et al. Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials. Thromb Haemost 2022; 122 (10) 1757-1766
11 Khorana AA, Palaia J, Rosenblatt L. et al. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J Immunother Cancer 2023; 11 (01) e006072
12 Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer 2021; 9 (01) e001719
13 Gong J, Drobni ZD, Alvi RM. et al. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 2021; 158: 99-110
14 Moik F, Chan WE, Wiedemann S. et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021; 137 (12) 1669-1678
15 Roopkumar J, Swaidani S, Kim AS. et al. Increased incidence of venous thromboembolism with cancer immunotherapy. Med 2021; 2 (04) 423-434
16 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829